Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure

Mechanisms and Clinical Applications: A Machine-Generated Literature Overview

Buch | Hardcover

528 Seiten

2024 | 2024 ed.
Springer Verlag, Singapore
978-981-97-7567-5 (ISBN)

Titel nicht im Sortiment

Artikel merken

The book delves into the development and therapeutic potential of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of diabetes and cardiovascular diseases. It explores their mechanism of action, cardiovascular benefits, and role in primary and secondary protection from renal and cardiovascular diseases. The book also highlights their emerging opportunities in the management of myocardial infarction, diabetic cardiomyopathy, and congestive heart failure. It provides a comprehensive review of preclinical and clinical information on the cardiovascular advantages of SGLT2 inhibitors. Additionally, the book explores selective drugs and their effects on cardiovascular events, mortality, and safety outcomes in individuals with type 2 diabetes.

The book is a valuable resource for researchers, healthcare professionals, and individuals interested in the field of SGLT2 inhibitors and their impact on diabetes and cardiovascular health.

Dr. Mukesh Nandave is an In-charge Director of the School of Pharmaceutical Sciences, Associate Dean (Research), and head of the Department of Pharmacology and Pharmaceutical Biotechnology at Delhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, New Delhi, India. He has earlier served as associate professor and head of the Department of Pharmacology at NMIMS University, Mumbai (2010-2017). He has also worked as a research scientist in the Medical Affairs and Clinical Research Department of Ranbaxy Research Laboratories (currently known as Sun Pharmaceutical Industries Limited, Gurugram). Dr. Nandave earned his Ph. D. in pharmacology from AIIMS, Delhi, and received his post-doctoral training from the Division of Cardiothoracic Surgery, the Ohio State University Medical Center, Columbus, USA. For more than 20 years, Dr. Nandave has investigated the role of nutraceuticals, herbomineral formulations, and phytoconstituents for myocardial ischemia & reperfusion injury, diabetes, obesity, and pain management. His lab received more than 3.5 crore total funding from Govt. (DBT, DST, ICMR, and AYUSH) as well as industry (Pharmazz, Dabur, Fertis India, Charak Pharma, Madhavbaug, and Sandu Pharma). He has published over 100 papers in peer-reviewed national and international journals, books, and book chapters. Dr. Nandave has received numerous awards including the Distinguished Leadership Award of the International Academy of Cardiovascular Sciences; Prof. S. C. Lahiri Oration and G. Achari Gold Medal by the Indian Pharmacological Society; Association of Pharmaceutical Teachers of India (APTI) Young Pharmacy Teacher of the Year Award, Early Investigator Award by International Society for Heart Research, Prof. Duggirala Visweswaram & Prof. Sreemantula Satyanarayana Prize; Best Research Output of the Year for 2014-2015, 2013-2014, and 2012-2013 Award" of SVKM's NMIMS University. Dr. Nandave is secretary general, of the International Academy of Cardiovascular Sciences (IACS)-India section and treasurer of the Society for Promotion and Research of Cardiovascular Sciences (SPARCS). He is a life member of various professional bodies including the International Society for Heart Research (ISHR), the International Academy of Cardiovascular Sciences (IACS); the Indian Pharmacological Society (IPS); the Indian Pharmaceutical Association (IPA); the Association of Physiologist and Pharmacologist of India (APPI); Association of Pharmaceutical Teachers of India (APTI); and Society for Ethnopharmacology.

Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry.- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes .- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes.- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction.- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy.- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure.- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors.- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes.- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor's effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.

Erscheinungsdatum	09.08.2024
Zusatzinfo	9 Illustrations, color; 1 Illustrations, black and white
Verlagsort	Singapore
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizin / Pharmazie ► Allgemeines / Lexika
	Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Pharmazie
Schlagworte	Congestive Heart Failure • Mechanisms of SGLT2 inhibitors for cardiovascular benefits • Myocardial Infarction • SGLT2 inhibitors in cardiovascular outcomes • SGLT2 inhibitors in type 2 diabetes
ISBN-10	981-97-7567-1 / 9819775671
ISBN-13	978-981-97-7567-5 / 9789819775675
Zustand	Neuware